10x Genomics, Inc. — Director's Dealing 2021

Dec 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-12-21

Reporting Person: CRUTCHFIELD BRADFORD (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-21	Class A Common Stock	M	4688	$1.20	Acquired	47743	Direct
2021-12-21	Class A Common Stock	M	49910	$5.04	Acquired	97653	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-21	Stock Option (right to buy)	$1.2	M	4688	Disposed	2027-10-18	Class A Common Stock (4688)	Direct
2021-12-21	Stock Option (right to buy)	$5.04	M	49910	Disposed	2028-11-02	Class A Common Stock (49910)	Direct

Footnotes

F1: This option, originally for 25,000 shares, of which 25,000 shares have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vested each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F2: This option, originally for 125,000 shares, of which 63,243 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vested each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.